COPENHAGEN/LONDON (Reuters) -Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

HONG KONG – Asian shares fell Monday and U.S. futures and the dollar weakened after Moody’sRatings downgraded the sovereign ...

Markets don't seem to have fully digested Moody's downgrade of the U.S. credit rating, Mitsubishi UFJ Morgan Stanley ...

U.S. stocks are set to wrap a winning week as tariff and trade fears ease, President Trump winds down his Middle East trip ...

Wall Street cruised to the finish of its strong week on Friday, as U.S. stocks glided closer to the all-time high they set ...